Endogenex, Inc. reported on July 8 that enrollment has been completed in its pivotal ReCET clinical study, a prospective, randomized, double-blinded and sham-controlled trial evaluating an investigational endoscopic procedure in adults with inadequately controlled type 2 diabetes. The study enrolled 350 participants across approximately 40 sites in the United States and Australia under a U.S. Food and Drug Administration (FDA) Investigational Device Exemption.
The enrollment milestone moves Endogenex beyond small feasibility studies and into the follow-up period that will determine whether targeting the duodenum can produce a reproducible improvement in glycaemic control. The primary endpoint is the change in glycated haemoglobin, or HbA1c, from baseline at six months, with all participants followed for 12 months.
ReCET refers to the endoscopic intestinal re-cellularization therapy being studied, while the company currently identifies the investigational delivery platform as the pulsENDO system. It uses nonthermal pulsed electric fields to treat mucosal and submucosal tissue in the duodenum, with the aim of initiating cellular regeneration and improving metabolic signalling between the gut and other organs involved in glucose regulation.
The procedure remains investigational and is not available for commercial sale in any geography. FDA Breakthrough Device designation and approval of the Investigational Device Exemption have helped Endogenex advance its clinical programme, but neither status establishes that ReCET is safe or effective, nor do they permit routine marketing.
Why does full enrollment matter more here than in a routine device feasibility study?
Completing enrollment is an operational milestone rather than a clinical result. No conclusion about the effectiveness of ReCET can be drawn until the randomized groups complete follow-up and the prespecified analysis is performed.
The significance lies in the scale and design of the study. Enrolling 350 participants into an invasive, sham-controlled metabolic procedure requires more complex coordination than recruiting for an observational study or testing a conventional glucose-lowering medicine. Participants must meet metabolic criteria, be suitable for upper gastrointestinal endoscopy and accept the possibility of undergoing a sham procedure.
The first participant entered the pivotal study in October 2024. Reaching full enrollment across approximately 40 sites suggests that Endogenex and its investigators were able to establish referral pathways between endocrinology, primary care, gastroenterology and metabolic medicine. Those pathways could become relevant to eventual commercial adoption if the procedure succeeds, because ReCET does not fit neatly within one existing medical specialty.
The study includes adults aged 22 to 70 with HbA1c levels between 7.5% and 10.5% and a body mass index between 27 and 40 kilograms per square metre. Eligible participants were required to have type 2 diabetes for at least six months and to be receiving two to four non-insulin glucose-lowering medicines, or monotherapy with a GLP-1 or combined GLP-1 and GIP medicine, on a stable regimen before baseline.
Current or recent extended insulin use is excluded. The trial is therefore testing ReCET in patients with insufficient glycaemic control who have not yet progressed to sustained insulin treatment, rather than across the full spectrum of type 2 diabetes.
That positioning may eventually influence the intended use sought from the FDA. Even if the primary endpoint is positive, the evidence would relate to a defined population with specific HbA1c, body mass index and medication characteristics. It would not establish effectiveness in people with type 1 diabetes, insulin-dependent type 2 diabetes or substantially different metabolic risk profiles.
Can the sham-controlled design isolate ReCET’s effect from medication and procedure bias?
The pivotal design is one of Endogenex’s most important assets. Participants are randomly assigned to ReCET or a sham endoscopic procedure, with blinding intended to reduce the expectation effects that can influence behaviour, medication adherence and reported outcomes after an intervention.
Sham controls are particularly important for endoscopic therapies because undergoing a procedure can itself change patient behaviour. Participants may improve their diet, take medicines more consistently or increase physical activity after receiving what they believe could be an active intervention. Without a sham group, those changes could be incorrectly attributed to the device.
The endoscopist delivering the procedure cannot realistically be unaware of whether pulsed electric field energy is being applied. Participant and outcome-assessor blinding can nevertheless reduce several major sources of bias, provided the sham procedure is sufficiently credible and the analysis preserves the randomized comparison.
Medication management will require similar discipline. Changes in glucose-lowering treatment, use of rescue medication and differences in adherence could materially affect HbA1c. The inclusion of a secondary endpoint measuring the proportion of participants who reach an HbA1c of 7% or below without rescue medication should help distinguish a device-associated effect from improvement produced by treatment escalation.
Participants in the sham arm may cross over to receive the Endogenex procedure after completing the 12-month observation period. This offers delayed access to the investigational treatment while preserving the controlled comparison for the study’s principal follow-up period.
The trial is also described as adaptive, indicating that prespecified design elements may permit modification based on accumulating information without compromising the study’s validity. The value of that approach will depend on which adaptations were allowed, how the statistical plan controls error and whether the final analysis remains straightforward for regulators and clinicians to interpret.
Geographic diversity is another consideration. Conducting the study in the United States and Australia should test the procedure across multiple centres and care environments, but it does not establish performance in every healthcare system or patient population. Broader post-approval evidence could still be needed to understand outcomes across different ethnic groups, medication patterns and endoscopy practices.
What does earlier REGENT-1 evidence establish, and what does it still leave unproven?
The rationale for the pivotal study is supported by REGENT-1 Australia and REGENT-1 United States, two multicentre proof-of-concept studies involving a combined 71 adults with inadequately controlled type 2 diabetes. Results from the integrated analysis were published in the peer-reviewed journal Diabetes, Obesity and Metabolism in February 2026.
The publication reported that no device-related or procedure-related serious adverse events occurred among the 71 participants and that the procedure was technically completed in every case. These findings support procedural feasibility, but the sample remains too small to identify uncommon complications or define the long-term safety profile of treating duodenal tissue with pulsed electric fields.
The highest-intensity treatment cohort, which received a double application using a second-generation catheter, recorded a mean HbA1c reduction of 1.5 percentage points at 48 weeks. Mean fasting plasma glucose decreased by 2.3 millimoles per litre, body weight declined by 5.4 kilograms and continuous glucose-monitoring time in range increased from 55.8% to 82.1%.
The investigators also observed a dose-related pattern, with higher energy delivery, double application and the newer catheter associated with larger or more sustained metabolic changes. That pattern strengthens the hypothesis that the intervention produced a biological effect, but it does not confirm which component of the procedure was responsible.
REGENT-1 was designed primarily to examine safety, feasibility and dose selection. It did not provide the same randomized, blinded comparison now built into the pivotal trial. Outcomes from the most intensive cohort could have been influenced by baseline differences, medication adherence, weight loss, behavioural changes or other factors not fully controlled in a proof-of-concept programme.
The reported improvement in body weight creates both an opportunity and an interpretive challenge. Weight reduction is clinically relevant in type 2 diabetes and could be part of the procedure’s value. However, because weight loss itself can lower HbA1c and improve insulin sensitivity, the pivotal analysis will need to examine whether the glycaemic effect is fully explained by weight change or whether additional metabolic activity is evident.
The earlier findings therefore provide a credible signal and a basis for the pivotal treatment settings. They do not establish that ReCET modifies the underlying course of type 2 diabetes, removes the need for medication or prevents cardiovascular, renal and microvascular complications.
Why is HbA1c at six months necessary but insufficient to define ReCET’s value?
HbA1c is a well-established measure of average glucose exposure and a relevant endpoint for diabetes studies. A randomized difference between ReCET and sham at six months would provide a clearer test of effectiveness than the uncontrolled changes reported in the earlier programme.
The magnitude of that difference will matter as much as statistical significance. A small average reduction could meet a statistical threshold in a 350-patient trial without necessarily supporting an invasive procedure. Clinicians, regulators and payers will examine whether the effect is large enough to justify endoscopy, procedural preparation and the associated safety burden.
The distribution of responses will also be important. A strong mean result driven by a limited group of high responders would have different implications from a consistent improvement across most participants. Baseline HbA1c, medication class, body mass index and other metabolic characteristics may help identify whether particular patients are more likely to benefit, although subgroup findings would need cautious interpretation.
Secondary endpoints include the proportion of participants reaching an HbA1c of 7% or below without rescue medication, continuous glucose-monitoring time in range, total body weight loss and adverse events. Together, these measures can show whether a change in HbA1c is accompanied by better day-to-day glucose control and whether improvement comes at the cost of hypoglycaemia or other complications.
Twelve-month follow-up will be essential because the commercial argument for a procedure depends heavily on durability. A single intervention becomes more attractive if benefit persists for a year or longer. A response that weakens substantially after six months would raise questions about repeat treatment, cumulative procedural risk and the economics of maintaining control.
The study is not designed or sized to establish a reduction in heart attacks, strokes, kidney failure or mortality. Medicines such as SGLT2 inhibitors and several GLP-1 receptor agonists already have extensive outcome data in defined patient populations. ReCET would initially need to compete on glycaemic control, durability, tolerability and treatment burden rather than proven cardiovascular or renal protection.
How could a duodenal procedure fit beside GLP-1 medicines and modern diabetes care?
Endogenex is pursuing a different therapeutic concept from conventional glucose-lowering drugs. The pulsENDO system delivers controlled electrical pulses to the duodenal lining, creating nonthermal cellular effects intended to support regeneration of mucosal and submucosal tissue.
The company’s hypothesis is that dysfunctional duodenal tissue contributes to impaired nutrient sensing and metabolic communication in type 2 diabetes. Treating that tissue may improve signalling involved in glucose regulation, insulin sensitivity, appetite and digestion.
This remains a therapeutic hypothesis under clinical evaluation. The procedure does not correct every biological process involved in type 2 diabetes, and a positive HbA1c result would not by itself prove that damaged duodenal tissue is the primary cause of the disease.
ReCET is more likely to enter care as an adjunct to medication than as an immediate replacement for pharmacotherapy. Participants in the pivotal study remain on glucose-lowering treatment, and the trial is designed to measure whether the procedure adds benefit in people whose existing non-insulin regimens are not providing adequate control.
That distinction is commercially important. GLP-1 receptor agonists and combined GLP-1 and GIP medicines can produce substantial glucose lowering and weight loss, while SGLT2 inhibitors offer established cardiorenal benefits in appropriate patients. Endogenex will need to show where an endoscopic intervention adds sufficient value without implying that it replaces evidence-based drug therapy.
The broader metabolic-device field is also becoming more active. Fractyl Health is evaluating Revita, a hydrothermal duodenal mucosal resurfacing procedure, primarily for maintaining weight loss after discontinuation of GLP-1 treatment. ReCET uses nonthermal pulsed electric fields and is being tested for glycaemic control in inadequately controlled type 2 diabetes.
Those differences in energy delivery, patient population, endpoints and treatment setting prevent direct comparisons. The parallel development programmes nevertheless show that the duodenum is emerging as a serious therapeutic target rather than remaining a speculative research concept.
What would hospitals need before ReCET could move beyond specialist trial centres?
A successful pivotal trial would address only part of the adoption pathway. ReCET requires upper gastrointestinal endoscopy, specialised equipment, a single-use or procedure-specific catheter, trained operators and coordination between the clinician managing diabetes and the gastroenterologist performing the intervention.
Hospitals would need to determine which department owns the treatment pathway, how candidates are referred and how medication is managed before and after the procedure. Without a clear service model, patients could become stranded between endocrinology and gastroenterology even when both specialties support the technology.
Training and procedural consistency will be critical. The dose-related findings from REGENT-1 suggest that the amount and pattern of duodenal treatment may affect outcomes. If effectiveness depends on achieving a specific treatment length or energy application, Endogenex will need to show that trained operators can reproduce the procedure across centres.
Safety evaluation must extend beyond the absence of serious complications in the initial 71-patient programme. The pivotal dataset should clarify rates of gastrointestinal pain, nausea, bleeding, tissue injury, treatment interruption and any device-related or procedure-related serious events. Reviewers will also examine whether complications vary by operator experience or patient anatomy.
Reimbursement may become the slowest part of the commercial pathway. A regulatory decision would not automatically provide a procedure code, payer coverage or an adequate payment rate. Insurers are likely to compare the total cost of the system, catheter, endoscopy suite, sedation and follow-up with the expected reduction in medication use or diabetes-related complications.
Endogenex has not yet demonstrated those economic outcomes. The company would need health-economic evidence showing which patients generate enough durable benefit to justify the procedure and whether ReCET reduces downstream utilisation rather than adding another layer of cost.
Does Endogenex have sufficient funding and regulatory clarity to reach a US submission?
Endogenex is privately held and does not have a public share price or an exchange-traded investor sentiment layer. Its capital position is nevertheless relevant because pivotal follow-up, regulatory preparation, manufacturing validation and commercial readiness can require substantial spending after enrollment ends.
The medical technology developer raised $88 million in a Series C financing completed in June 2024. A further $50 million extension led by Arboretum Ventures closed in March 2026, bringing total Series C financing to $138 million. Endogenex said the proceeds were intended to complete the pivotal study and support the pathway toward an FDA marketing decision.
The FDA approved the study’s Investigational Device Exemption in November 2023 and previously granted Breakthrough Device designation for the treatment of adults with type 2 diabetes whose blood glucose remains inadequately controlled by glucose-lowering medicines. Breakthrough status can facilitate regulatory interaction and prioritized review, but it does not lower the evidentiary standard to the point where an unsuccessful pivotal study could support marketing.
Endogenex has not publicly established a confirmed submission date in the enrollment announcement. The appropriate marketing pathway, the final evidence package and any additional manufacturing or clinical requirements will depend on the pivotal results and continued discussions with the FDA.
The $138 million Series C provides substantial backing for a private clinical-stage device company, but reaching approval is different from building a commercial organisation. Endogenex may eventually require additional financing, a strategic partner or both to scale manufacturing, support physician training, establish reimbursement and launch across a meaningful network of endoscopy centres.
Which pivotal findings would make ReCET a credible new category in metabolic care?
The decisive result will be the randomized difference in six-month HbA1c between ReCET and sham, supported by a clinically meaningful magnitude, an acceptable safety profile and consistency across the enrolled population. Improvement in time in range and the proportion of participants reaching an HbA1c of 7% or below without rescue medication would strengthen the interpretation.
Weight change must be analysed carefully rather than treated as a statistical nuisance. If ReCET improves both weight and glycaemic control, that combination could increase its clinical relevance. The evidence must still show whether the glucose effect remains meaningful after accounting for weight loss and medication changes.
Durability at 12 months will determine whether the procedure can credibly be presented as a longer-lasting intervention. Safety, operator consistency and the need for repeat treatment will shape the risk-benefit calculation just as much as the primary endpoint.
Full enrollment means the ReCET programme has finally reached the stage where its central claim can be tested without relying on an uncontrolled cohort or a promising mechanistic narrative. The next dataset must show whether pulsed electric field treatment of the duodenum adds measurable value to modern diabetes therapy, and whether that value is large and durable enough to justify moving diabetes care into the endoscopy suite.
